To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors
Provider Data DescriptionThis dataset contains all the data used in the publication cited above (PMID=26287032).
Baseline demographic and clinical variables are provided for time = 0 (baseline visit).
The primary outcome measures for the study are assessed at each time (0=baseline, 4=4 weeks, 8=8 weeks, and 12=12 weeks).
Summary measures that are calculated across the participant?s time on study (e.g., worst toxicities and compliance) are recorded on the time = 99 rows. Note that these are measures determined over the entire study period, not a specific time.
Notes: Missing data are denoted by a blank or a ?.? for each variable.
SponsorWake Forest University Health Sciences
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryRATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors.
PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.
ConditionsSexual Dysfunction Sexuality and Reproductive Issues Unspecified Adult Solid Tumor, Protocol Specific